Document is current
Any future updates will be listed below
-
Authors
Fougeroux, Cyrielle
Hagen, Sven Hendrik
Goksøyr, Louise https://orcid.org/0000-0003-4508-9857
Aves, Kara-Lee
Okholm, Anna Kathrine https://orcid.org/0009-0009-4352-0296
Morin, Candice
Lokras, Abhijeet Girish https://orcid.org/0000-0002-5617-0151
Baghel, Saahil Sandeep https://orcid.org/0000-0002-0512-2061
Foged, Camilla https://orcid.org/0000-0003-2812-5588
van de Vegte-Bolmer, Marga
van Gemert, Geert-Jan
Jore, Matthijs M.
Vidal-Calvo, Elena Ethel https://orcid.org/0000-0001-9655-2106
Gustavsson, Tobias
Salanti, Ali https://orcid.org/0000-0003-2207-5575
Theander, Thor Grundtvig
Nielsen, Morten Agertoug
de Jongh, Willem Adriaan https://orcid.org/0000-0001-7983-956X
Sander Bertelsen, Adam Frederik https://orcid.org/0000-0002-8782-7830
-
Funding
Funding for this research was provided by:
Novo Nordisk Fonden (NNF22SA0081890, NNF22SA0081890, NNF22OC0076808, NNF21OC0068192, NNF22OC0076055, NNF21OC0068192, NNF22OC0076055, NNF22SA0081890)
Det Frie Forskningsråd (Grant DFF-9041-00198B)
- License Information
-
More Information
Article History
Received: 25 January 2024
Accepted: 10 February 2025
First Online: 14 May 2025
Competing interests
: W.A.J., L.G., C. Fougeroux, M.A.N. and A.F.S.B. are listed as co-inventors on a patent application covering the Delivery of a cVLP-based modular vaccine platform in a nucleic acid format (P5856PC00). C. Fougeroux, L.G., A.F.S.B., W.A.J., S.H.H., T.G.T., A.S. and T.G. are shareholders of AdaptVac, a company commercializing VLP display technology and vaccine, including several patents. A.G.L., S.S.B. and C. Foged are listed as co-inventors on patent applications covering the use of nanoparticles for mRNA delivery. C. Foged consults for Lonza and Sanofi. All other authors declare no competing interests.
